Mobile apps are a fast paced technology that require ongoing iterations. At mySugr, we’ve learnt this first hand. A small change in something as “banal” as our welcome email can reverberate in unexpected ways throughout our 1.5 million user base. For better or worse, this means technology like ours doesn’t translate well into randomized clinical trials, the gold standard of prospective trials. By the time the publication date rolls around, we’re likely to be an entirely different animal.
A diabetes care program drives real world resultsTogether with ProSciento, we looked into the impact of the mySugr Bundle among our users. The mySugr Bundle is a subscription kit containing unlimited test strips, automatic supply refills, personalized coaching, and more. It is available to patients directly (out of pocket) and through health insurers and provider systems in Germany and the United States. Learn more about our digital population health management solution here. We looked into how people interact with the app just after registering, in the two months prior to receiving the mySugr Bundle and the two months after the bundle has arrived. We included data from people who measured their blood glucose levels on average three or more times per day during each period. Given the strict time frames and test frequency requirements for inclusion, and the recent launch of the mySugr Bundle in the U.S. market, the result was a pool of 52 participants with type 1, type 2, or latent autoimmune diabetes (LADA). The results are very encouraging. The population was already doing well and their diabetes management improved further:
- On average, participants’ blood glucose levels dropped from 154±55 mg/dl to 138±50 mg/dl
- Translated into HbA1c (by calculating the “estimated A1c”), this shows a mean drop from 6.7% to 6.3%
- This drop of 0.4% in an already “well controlled population” exceeds the 0.3% threshold for a therapy, device or medication to be seen as relevant